<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02902757</url>
  </required_header>
  <id_info>
    <org_study_id>15-000409</org_study_id>
    <secondary_id>NCI-2016-00583</secondary_id>
    <secondary_id>15-000409</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <nct_id>NCT02902757</nct_id>
  </id_info>
  <brief_title>FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma</brief_title>
  <official_title>Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron
      emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response
      in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a
      patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the
      tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the
      start of therapy may help identify very early therapy response in patients with glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT.

      II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and
      correlate them with objective response parameters such as Response Assessment in
      Neuro-Oncology (RANO) and survival.

      OUTLINE:

      Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one
      additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2015</start_date>
  <completion_date type="Anticipated">August 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glucose uptake</measure>
    <time_frame>From baseline up to 48 hours</time_frame>
    <description>Standardized uptake values (SUV) will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria</measure>
    <time_frame>One PET/CT 48 hours after start of therapy</time_frame>
    <description>SUV will be calculated for different organs and for regions of tumor. Further, regional target to background count-activity ratios will be established.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (FDG PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Treatment (FDG PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT SCAN</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Treatment (FDG PET/CT)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
    <other_name>fludeoxyglucose F 18</other_name>
    <other_name>Fludeoxyglucose F18</other_name>
    <other_name>Fluorine-18 2-Fluoro-2-deoxy-D-Glucose</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Treatment (FDG PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET SCAN</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven high grade glioma

          -  Intention to start therapy

        Exclusion Criteria:

          -  Severe psychiatric illness

          -  Inability to give written consent

          -  Breast feeding / pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Herrmann</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Herrmann</last_name>
      <phone>310-825-7125</phone>
    </contact>
    <investigator>
      <last_name>Ken Herrmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FDG</keyword>
  <keyword>PET/CT very early response (48 hrs)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

